. 2021 Jan 21;20:342–351. doi: 10.1016/j.omto.2021.01.011

Table 3.

Clinical trials evaluating CTLA-4 inhibitors for HNSCC treatment

NCT no.: ClinicalTrials.gov	Status	Intervention/treatment	Phase
NCT02812524	recruiting	Ipilimumab	1
NCT02919683	active, not recruiting	Nivolumab	2
NCT02919683	active, not recruiting	Ipilimumab	2
NCT02741570	active, not recruiting	nivolumab, ipilimumab	3
NCT02741570	active, not recruiting	cetuximab/Erbitux, cisplatin, carboplatin, fluorouracil	3
NCT02823574	active, not recruiting	Nivolumab	2
NCT02823574	active, not recruiting	Ipilimumab	2
NCT04080804	recruiting	nivolumab, relatlimab, ipilimumab	2
NCT03690986	recruiting	VX15/2503, ipilimumab, nivolumab	1
NCT03700905	recruiting	surgery + radiotherapy and chemotherapy	3
NCT03700905	recruiting	neoadjuvant nivolumab, adjuvant nivolumab, ipilimumab	3
NCT03162731	active, not recruiting	nivolumab, ipilimumab	1
NCT01935921	active, not recruiting	cetuximab, ipilimumab + radiotherapy	1
NCT03003637	recruiting	nivolumab	2
NCT03003637	recruiting	ipilimumab	2
NCT03098160	recruiting	Evofosfamide	1
NCT03098160	recruiting	ipilimumab	1
NCT04290546	recruiting	IL-15 superagonist (N-803)	1
		CIML NK cell infusion
		Ipilimumab
NCT04326257	recruiting	nivolumab + relatlimab	2
NCT04326257	recruiting	nivolumab + ipilimumab	2
NCT03620123	recruiting	nivolumab and ipilimumab	2
NCT03620123	recruiting	docetaxel	2
NCT03058289	recruiting	anti-CTLA-4 antibody	1
NCT03058289	recruiting	anti-CTLA-4 antibody	2

For more information, refer to https://clinicaltrials.gov/.